BRMS1L (BRMS1 like transcriptional repressor) functions as a metastatic suppressor through HDAC1-dependent transcriptional repression. As a component of the Sin3A-HDAC co-repressor complex, BRMS1L epigenetically silences oncogenic genes, particularly through histone H3K9 deacetylation at target promoters 1. Primary targets include FZD10 and genes involved in epithelial-mesenchymal transition (EMT), critical processes in cancer metastasis 1. BRMS1L is a downstream effector of the p53 family pathway; p53, p63, and p73 directly upregulate BRMS1L expression through conserved response elements, and ectopic BRMS1L expression inhibits cancer cell invasion and migration 2. In multiple cancer types, BRMS1L expression is downregulated and correlates with poor prognosis in breast, ovarian, and brain cancers 234. BRMS1L suppresses metastasis by inactivating the Wnt/β-catenin signaling pathway, and its loss promotes EMT and invasive phenotypes 31. MicroRNA-mediated downregulation of BRMS1L (via miR-106b, miR-155-3p, miR-96-182-183, and miR-934) drives oncogenic transformation and metastatic progression 1567. These findings establish BRMS1L as a therapeutic target and prognostic biomarker for cancer management.